https://www.selleckchem.com/pr....oducts/obeticholic-a
19/100 person-years versus 5.22/100 person-years, adjusted hazard ratio=0.781, P=0.04). For AF patients with an intermediate risk of stroke (ie. a single non-sex stroke risk factor) but at high bleeding risk, the use of OACs was still significantly associated with a better overall clinical outcome. For AF patients with an intermediate risk of stroke (ie. a single non-sex stroke risk factor) but at high bleeding risk, the use of OACs was still significantly associated with a better overall clinical outcome. To investigate the pr
إعجاب
علق
شارك
